Tips & advice

More Tips & advice articles

• The biggest penny share story of this decade

  By Tom Bulford, 24 May, 2012

  This decade will be defined by developments in biotechnology, says Tom Buford. Here, he explains the role biotech is playing in resolving the global food crisis.

• Nine investments our experts would buy into now

  By John Stepek, 24 May, 2012 -Subscriber only

  Should China’s slowdown worry us? And what’s going on in Greece? John Stepek talks to our panel of experts to find out what they're buying now.

• Keep calm as the market panics

  By Phil Oakley, 24 May, 2012

  With markets near panic and the outlook far from rosy, you need to keep calm and spread your money around if you want to hang on to your wealth, says Phil Oakley. Here, he picks a few ways to help you do just that.

• What is an exchange-traded fund?

  By Tim Bennett, 24 May, 2012

  Tim Bennett looks at one of our favourite investments - exchange traded funds - and explains what they are, why we like them, and what their drawbacks are.

• What to do as Britain's economy falters

  By Matthew Partridge, 24 May, 2012

  Britain's economy is set to get worse before it gets better as we battle against headwinds from Europe. But there are still opportunities out there, says Matthew Partridge, Here, he tips a stock that should weather the tough times.

• Is it time to buy gold miners?

  By Bengt Saelensminde, 23 May, 2012

  With gold miners held in such low esteem by investors, now could be your chance to buy into this unloved sector, says Bengt Saelensminde. Here, he tips one exchange-traded fund to buy now.

• With Burberry you get what you pay for

  By Phil Oakley, 23 May, 2012

  British fashion label Burberry is having no problems selling to the style-conscious abroad. So, should you buy shares in the iconic brand? Phil Oakley investigates.

• You can be as rude as you like to these people

  By Tom Bulford, 22 May, 2012

  Fraudsters touting fake shares have become a serious threat to investors. Tom Bulford explains how to avoid getting caught out - and what to do if you're approached.

• A share to buy instead of Facebook

  By Phil Oakley, 23 May, 2012

  Facebook's shares have fallen back since its much-hyped IPO last week. But they are still massively overvalued, says Phil Oakley. Here he explains why, and tips a tech stock to buy instead.

• Why you’ll pay for the Greek exit

  By Bengt Saelensminde, 21 May, 2012

  A Greek default and spectacular exit from the euro are looking ever more certain, says Bengt Saelensminde. But who stands to lose the most?

• What is a firm’s true profit?

  By Tim Bennett, 18 May, 2012 -Subscriber only

  Knowing how much profit a firm makes is vital. But company accounts rarely make it straightforward, says Tim Bennett. Here, he explains how to find the figures you need to know.

• Three US growth stocks

  By Ken Stuzin, 18 May, 2012

  High-quality growth stories still exist within the US market, says professional investor Ken Stuzin. Here, he tips three such stocks to buy now.

• Can Tesco turn things around?

  By Bengt Saelensminde, 18 May, 2012

  Although Tesco's revenues look fine, a closer look at their accounts reveals something more worrying. Bengt Saelensminde examines the reports and asks whether the supermarket can turn its fortunes around.

• Gamble of the week: Resourceful packaging designer

  By Paul Hill, 18 May, 2012 -Subscriber only

  This designer of food and drink packaging has so far proved resilient against the downturn, says Paul Hill.

• Share tips: A supermarket with its own strategy

  By Paul Hill, 18 May, 2012 -Subscriber only

  This British supermarket has decided to abstain from the price war affecting its rivals, says Paul Hill. And the strategy looks to be paying off.

• Why 'mark to market' matters

  By Tim Bennett, 18 May, 2012

  Tim Bennett explains 'mark to market - what it is, how it can make life difficult for investors, and what you can do about it.

• Shares in focus: Syngenta - fertilising growth

  By Phil Oakley, 17 May, 2012 -Subscriber only

  Syngenta is well placed to benefit from the growing world population. So, should you buy its shares? Phil Oakley investigates.

More articles»